| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Elevance Health, Inc.$394.79
-2.94 (-0.74%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
68.76 B
EPS
25.18
P/E Ratio
12.41 $
Value Trade
581.94 M
SEC Financials
Q1 2026Dilution Risk
Revenue
50.18 B
Operating CF
4.33 B
Total Assets
125.83 B
Total Liabilities
81.78 B
Equity
43.90 B
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
35.56 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 22, 2026
Overview
Volume
201.08 K
52 Week Range
273.71 - 443.29
% held by Insiders
0.3 %
% held by Institutions
92.58 %
Enterprise Value
101.61 B
Total Shares
220.73 M
Short %
3 %
Float Shares
220.51 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 16%
Large Pharma (rank 761 of 905)
Percentile RankElevance Health, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ELV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ELV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ELV
Jun 17, 2026Elevance Health Announces $640 Million Investment in Affordable Housing Over the Past Five Years, Surpassing $1 Billion in Total Commitment Nationwide
Elevance Health has announced that it has invested $640 million in affordable housing over the past five years. This investment contributes to a total commitment of over $1 billion nationwide. The company aims to address housing challenges and improve community health outcomes through these efforts.
Read more →-ELV
Jun 15, 2026Elevance Health Makes Chronic Care Easier to Navigate With Connected, Personalized Support
Elevance Health has introduced a new initiative aimed at simplifying chronic care management. The program focuses on providing connected and personalized support to patients, enhancing their navigation through the healthcare system. This move is expected to improve patient experiences and outcomes in managing chronic conditions.
Read more →-ELV
Apr 22, 2026Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
Elevance Health reported strong first quarter 2026 results, surpassing expectations and raising its full-year adjusted EPS guidance. The company experienced growth in operating revenue, primarily driven by higher premium yields. However, it also noted a decrease in operating gain and anticipated declines in certain membership segments, reflecting challenges in the Medicaid and Medicare Advantage areas.
Read more →Competitive Position
How ELV ranks across every disease it competes inCompetitive Position is a premium feature
See how ELV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial